ResultsIQ

ResultsIQ › Latest results › Cohance Lifesciences Limited

Cohance Lifesciences Limited Q4 FY25 results deck summary

NSE: COHANCE · BSE: 543064

Results deck of 28 May 2025, summarised by AI from the filing.

Cohance reports Q4 FY25 revenue up 19.9% YoY to ₹8,412 mn and guides FY26 double-digit revenue growth.

Key takeaways

  1. Q4 revenue Q4 FY25 revenue ₹8,412 mn, up 19.9% YoY, driven by Pharma CDMO and Spec Chem.
  2. FY26 guidance Management expects strong double-digit revenue growth in FY26 and EBITDA margins in low 30s.
  3. Pharma CDMO Pharma CDMO grew 18% YoY in FY25 to ₹11.3 bn, with Phase III pipeline at 9 molecules.
  4. Margin pressure Adjusted EBITDA margin declined to 31.3% in Q4 FY25 from 36.4% YoY due to business mix.

Original filing on BSE

Cohance Lifesciences Limited Q1 FY27 results

As filed: Revenue ₹422 cr (−23% year on year), EBITDA ₹1.2 cr (−99% year on year), PAT −₹45.2 cr (−198% year on year), EBITDA margin 0.3% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹619 cr (+54% year on year), EBITDA ₹98.7 cr (+33% year on year), PAT ₹8.3 cr (−30% year on year), EBITDA margin 15.9% (−247 bps). Score 55 of 100, In line with trend. EBITDA margin fell 247 bps year on year. Tax rate 58%. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −12.6% in 30 days (Nifty 500: −0.8%).
  • Q3 FY26: Revenue ₹482 cr, EBITDA ₹103 cr, PAT ₹47.3 cr, EBITDA margin 21.3%. Not scored. No result for the same quarter last year. Share price after the results: −15.6% in 29 days (Nifty 500: −9.6%).
  • H1 FY26: Revenue ₹981 cr, EBITDA ₹236 cr, PAT ₹147 cr, EBITDA margin 24.1%. Not scored. No result for the same half-year last year. Share price after the results: −22.3% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹484 cr, EBITDA ₹104 cr, PAT ₹53.0 cr, EBITDA margin 21.5%. Not scored. No result for the same quarter last year. Share price after the results: −0.6% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹330 cr, EBITDA ₹66.0 cr, PAT ₹44.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.9% in 30 days (Nifty 500: +3.7%).

Past price moves after results do not indicate future moves. Not a recommendation.

Cohance Lifesciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.